Generex Biotechnology Corporation's wholly-owned subsidiary, Antigen Express, Inc. has received Notices of Allowance from the United States Patent Office (USPTO) relating to applications for the use of therapeutic vaccines targeting human papilloma virus (HPV) caused cancers as well as to potentially pandemic strains of influenza virus.
The company has previously received allowances of broad claims surrounding the use of its Ii-Key hybrid technology platform. Both applications relate to vaccines designed using this platform, which was also used to design its AE37 vaccine that is currently in a late phase II trial to prevent relapse in patients who have had breast cancer.
The company has previously published preclinical studies on lead compounds targeting HPV and conducted clinical trials of influenza targeted vaccines in healthy volunteers. While there are prophylactic vaccines on the market to prevent HPV infection, none are approved for use in the therapeutic setting to treat existing cancers caused by HPV. The added potency of Antigen Express vaccines derives from its ability to activate CD4+ T helper cells, which are critical in the generation of a novel immune response.
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.